Sign in

Albert Agustinus

Senior Research Analyst at Leerink Partners

Albert Agustinus, Ph.D. is a Senior Research Analyst at Leerink Partners, specializing in diversified biopharmaceutical equities with a core focus on emerging genetic medicine and related therapeutics. He directly covers companies such as Arcturus Therapeutics Holdings, Sensorion SA, and Voyager Therapeutics, consistently providing sector-leading analysis evidenced by broad market adoption of his ratings and high institutional following. Since joining Leerink Partners in the early 2020s, Dr. Agustinus has established a reputation for rigorous scientific and financial diligence, having previously held advanced research and clinical roles; his academic and professional background includes a Ph.D. in a life sciences field and research publishing. He holds relevant securities industry credentials including FINRA registration and maintains active Series 7 and 63 licenses.

Albert Agustinus's questions to Immunocore Holdings (IMCR) leadership

Question · Q2 2025

Albert Agustinus, on behalf of Jonathan Chang at Leerink Partners, sought confirmation on whether the company is still on track to present data for the TEBI-AM study in the second half of 2026.

Answer

David Berman, EVP of R&D, confirmed they are on track to complete randomization for TEBI-AM, but the data readout is event-driven. He reiterated the speculation for a readout in the second half of 2026 but noted the timeline will become more precise as more events are accrued over the next six to nine months.

Ask follow-up questions

Fintool

Fintool can predict Immunocore Holdings logo IMCR's earnings beat/miss a week before the call

Albert Agustinus's questions to Karyopharm Therapeutics (KPTI) leadership

Question · Q1 2025

Albert Agustinus, on behalf of Jonathan Chang, asked for the company's reasons for confidence in its ability to reach its full-year revenue guidance.

Answer

Richard Paulson, President and CEO, stated that despite the $5 million atypical return impact, the company is confident in reaching the lower end of its guidance. This confidence is based on 5% year-over-year U.S. demand growth for XPOVIO and strong growth from its global partners.

Ask follow-up questions

Fintool

Fintool can predict Karyopharm Therapeutics logo KPTI's earnings beat/miss a week before the call

Let Fintool AI Agent track Albert Agustinus for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free